We are live on ! Find out more

CollPlant Biotechnologies

CLGN

Market cap $7.79M

4.12 USD

+0.08

1.98%

At close Updated Sep 24, 4:00 PM EDT

Pre-market

After hours

4.12

0.00

0%

1 day

1.98%

5 days

-0.72%

1 month

36.88%

3 months

22.62%

6 months

-42.05%

Year to date

-72.16%

1 year

-83.78%

5 years

-97.51%

10 years

-95.4%

About: CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

Employees: 39

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads

Peer-reviewed study published by ACM: LightSolver's LPU architecture demonstrated significantly lower projected time-to-solution, compared to state-of-the-art algorithms running on a GPU REHOVOT, Israel, September 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced the publication of joint research conducted by its subsidiary LightSolver Ltd.

LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads

CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq confirms the Company satisfies continued listing criteria under Listing Rule 5550(a)(2), officially closing the compliance matter Follows the recent completion of the LightSolver acquisition, marking CollPlant's strategic expansion into high-performance computing (HPC) and photonics REHOVOT, Israel, Sept. 22, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.

CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement

CollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing Transcript

CollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing Transcript

CollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing Transcript

CollPlant to Host LightSolver Investor Webinar on September 17, 2026

REHOVOT, Israel, Sept. 10, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.

CollPlant to Host LightSolver Investor Webinar on September 17, 2026

COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION

LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant's Board as the Company advances the commercialization of its newly acquired photonic computing technology REHOVOT, Israel, Sept. 4, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.

COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION

COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR

Technological Edge - LightSolver advances the development of the world's first Laser Processing Unit (LPU) – an energy-efficient, pure photonic computing platform Accelerated Growth Path - The transaction positions LightSolver to accelerate its path towards commercialization and expand engagements with strategic partners. REHOVOT, Israel, Sept.

COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR

COLLPLANT ANNOUNCES REVERSE SHARE SPLIT

REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.

COLLPLANT ANNOUNCES REVERSE SHARE SPLIT

COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS

LightSolver is pioneering pure photonic computing, bringing a new computing architecture to the public markets to address the speed, energy and heat limitations of semiconductor-based computing LightSolver has developed the world's first Laser Processing Unit™ (LPU™), combining the advantages of classical and quantum computing in a compact platform that operates without cryogenic or other extreme conditions and is designed for commercial deployment. Commercial validation is underway with global leaders across mission-critical industries, including Boeing, a top-tier global financial institution, leading defense companies, oil and gas and energy companies, and leading engineering software organizations.

COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT

REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof), unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares, in a private placement at a combined purchase price of $0.34 per ordinary share and accompanying warrants (or $0.3399 per ordinary share equivalent and accompanying warrants). The series A warrants will have an exercise price of $0.34 per share, will be exercisable on the date of shareholder approval (the "Shareholder Approval Date") and will expire two years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics applications, today announced financial results for the first quarter of 2026 and provided a corporate update. "In the first quarter of 2026, we initiated discussions with several leading strategic players to explore potential collaborations, primarily in the medical aesthetics field," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant Biotechnologies.

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

See News Rankings

Price charts implemented using Lightweight Charts™